

Docket No: AM1006

Patent

HE UNITED STATES PATENT AND TRADEMARK OFFICE

In re of Application of:

Hassan M. ELOKDAH et al.

Application No.:

10/731.074

Group Art No.:

Filed: For:

JUN 2 3 2004

December 9, 2003 Examiner:

SUBSTITUTED INDOLE OXO-ACETYL AMINO ACETIC ACID

DERIVATIVES AS INHIBITORS OF PLASMINOGEN ACTIVATOR

INHIBITOR (PAI-1)

Confirmation No.:

Customer Number:

25291

Mail Stop Amendment Commissioner for Patents

PO Box 1450

Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

1. **Preliminary Statements**

In accordance with 37 CFR 1.97 and 1.98, Applicants submit herewith patents, publications, or other information of which they are aware, which they believe may be material to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 CFR 1.56. This Information Disclosure Statement is not to be construed as a representation that: (i) a search has been made; (ii) the information is material to the examination of this application; (iii) additional information material to the examination of this application does not exist; (iv) the information, protocols, results and the like reported by third parties are accurate or enabling; or (v) the information constitutes prior art to the subject invention.

CERTIFICATE OF MAILING 37 CFR §1.10

I hereby certify that this paper and the documents referred to as enclosed therein are being deposited with the United States Postal Service on the date written below in an envelope as "Express Mail Post Office to Addressee" Mailing Label Number EV238504895US addressed to the Mail Stop Amendment, Commissioner for Patents, PO Box 1450, Alexandria, VA 22313-1450.

Docket No: AM100639
Patent

2. Identification of Time of Filing This Information Disclosure Statement is filed within three months of the filing date of the application. a. $\overline{\boxtimes}$ b. is filed before the mailing date of a first Office Action on the merits. is filed before the mailing date of a first Office Action after the filing of a C. request for continued examination under 37 CFR 1.114. is filed after the period specified in 2(a), 2(b) or 2(c) above, but before the d. mailing date of a final action under 37 CFR 1.311. This statement includes a certification under 37 CFR 1.97(e) or the fee set forth in 37 CFR 1.17(p). is filed after the mailing date of a final action or Notice of Allowance but e. before payment of the issue fee. This statement includes (i) a certification under 37 CFR 1.97(e), and (ii) the fee set forth in 37 CFR 1.17(p). Certification under 37 CFR 1.97(e) and 1.704(d) 3. The undersigned attorney certifies that each item of information contained in the Information Disclosure a. Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the statement, or b. that no item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the person signing the certification after making reasonable inquiry, was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the statement. certifies that each item of information contained in the Information C. Disclosure Statement was cited in a communication from a foreign application patent office in a counterpart foreign application and was not received by any individual designated in 37 CFR 1.56(c) more than thirty (30) days prior to the filing of the statement. 図 **Newly Cited Information** A legible copy of the patents, publications or other information cited on the attached form PTO 1449 is enclosed, except that no copy of a pending U.S. application is enclosed, and if this patent application was filed or entered the national stage after June 30, 2003, no copy of a U.S. patent or U.S. patent application publication is enclosed. In addition, a copy of the International Search Report from the corresponding PCT application is enclosed. **Previously Cited Information** No copy of the patents, publications or other information cited on the attached form PTO-1449 is enclosed because it has been previously cited by or submitted to the Office in a prior application which is relied upon for an earlier filing date under 35 USC 120. Prior application is Application Number , filed on for

Docket No: AM100639
Patent

 \boxtimes Concise Explanation Documents cited above which are not in the English Language a. have been explained in the specification. b. \boxtimes have an abstract (or other concise explanation) in English enclosed. Form PTO-1449 is enclosed in duplicate. **Fees** Fee for filing under 37 CFR 1.97(c) or (d) Fee: \$180.00 Method of Payment of Fees: Charge Deposit Account No. 07-1060 in the amount of \$0.00 A duplicate of this statement is enclosed. Instructions as to Overpayment/Underpayment: Credit any overpayment and charge any underpayment to Deposit Account No. 07-1060.

> Christine P. Bellon Attorney for Applicants Reg. No. 41,611

Wyeth Patent Law Department Five Giralda Farms Madison, NJ 07940 Tel. No. (617) 665-6045

					P	E vc						
Cubosis	to for fo	rm 1440/	DTO		0	6	7	Cor		te if Know	n	
Substitute for form 1449/PTO					NUL	2 3 2004	Application Number		10/731,074			
INFORMATION DISCLOSURE						Š	Filing Date		December 9, 2003			
STATEMENT BY APPLICANT (use as many sheets as necessary)					100	CAPE.	First Named Inventor		Hassan M. Elokdah			
	(use	e as man	y sheets a	is neces	SAME	T& TRADE	Group Art Uni Examiner Nar		 			
Sheet 1 of 1			Attorney Docket Number AM100639									
									7 7 110			
		U.S. Patent Document				U.S. PA	TENT DOCUMENTS			Book Octoor Vision		
Examiner Cite Initials* No.		Number (If known)		Kind Code (If Known)			ntee or Applicant Document Document Date of Publica Cited Docum MM-DD-YY		ent		Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
	1.			<u> </u>								
			· - ·		FO	REIGN F	PATENT DOC	UMENTS	-			
	<u> </u>		Foreig	n Patent Do							Pages, Columns,	
Examiner Initials*	Cite No.			Number		Kind Code (If Known)	Name of Patentee or Applicant of Cited document		Date of Publication of Cited Document MM-DD-YYYY		Lines, Where Relevant Passages or Relevant Figures Appear	т
	2.	EP	EP 1 09	2 716	A2		Guillaume de	Nanteuil, et	4/18/01			
	"						al					Abstract
	ł		L			L	<u> </u>					only
			OTHER				I PATENT LIT				1	
Examiner Initials*	Cite No.			Inc item	lude name (book, mag	azine, journal, s	CAPITAL LETTERS), title erial, symposium, catalog	, etc.) date, page(s),	appropr volume-	iate), title of the issue number(s),		Т
madis	3.	1				pub	lisher, city and/or country	where published.				
	J	I										

Examiner	Date
Signature	Considered